Actos (Pioglitazone) Label Updates 2020 to 2026

Pioglitazone Regulatory Overview: 1999 to 2020

Pioglitazone earned FDA approval on July 15, 1999, as a PPAR-gamma agonist indicated for type 2 diabetes mellitus as monotherapy or combination therapy. By the time the 2020s began, the drug had already survived one of the most contentious post-market safety debates in endocrinology: the bladder cancer signal.

The Bladder Cancer Controversy

A 2011 FDA Drug Safety Communication warned of a possible increased bladder cancer risk with pioglitazone use exceeding 12 months [1]. The agency required Takeda to conduct a 10-year observational study through Kaiser Permanente Northern California. That study, completed in 2016, found no statistically significant increase in bladder cancer risk (HR 1.06, 95% CI 0.89 to 1.26) among pioglitazone users compared with matched controls [2]. The finding prompted the FDA to remove its earlier recommendation against prescribing pioglitazone to patients with active bladder cancer history, though cautionary language remained.

Heart Failure: The Persistent Boxed Warning

The boxed warning for congestive heart failure (CHF) has been on the label since 2007. Pioglitazone causes dose-dependent fluid retention. In the PROactive trial (N=5,238), heart failure hospitalizations occurred in 5.7% of pioglitazone-treated patients versus 4.1% on placebo [3]. The label contraindicates use in NYHA Class III or IV heart failure and requires monitoring for signs of fluid overload in all patients. This warning was not removed or downgraded during the 2020 to 2026 period.

2020 to 2021 Label Changes: Bone Fractures and Pharmacovigilance Refinements

The 2020 and 2021 prescribing information updates focused primarily on two areas: fracture risk data presentation and post-marketing adverse event language. These changes were modest but clinically relevant.

Updated Fracture Risk Data

The Warnings and Precautions section received new long-term fracture incidence numbers. Pooled data from randomized controlled trials showed that women taking pioglitazone experienced distal limb fractures (foot, hand, wrist, upper arm) at a rate of 1.9 per 100 patient-years compared with 1.1 per 100 patient-years on placebo [4]. The label clarified that fracture risk applied to women regardless of menopausal status, a distinction that prior versions had not made explicit.

For men, the data showed no statistically significant increase in fracture rates (0.8 vs. 0.6 per 100 patient-years), and the label reflected this asymmetry. The revision prompted the American Association of Clinical Endocrinology (AACE) to recommend dual-energy X-ray absorptiometry (DEXA) screening before initiating pioglitazone in postmenopausal women already at elevated fracture risk [5].

Post-Marketing Adverse Reactions Table

The 2021 update expanded the post-marketing experience section to include updated reporting frequencies for macular edema. Cases had been collected through the FDA Adverse Event Reporting System (FAERS) since 2005, and the new language specified that macular edema reports occurred predominantly in patients with pre-existing diabetic retinopathy [4]. Prescribers were advised to refer patients for ophthalmologic evaluation if visual changes occurred within the first 6 months of therapy.

2022 Label Revision: Sentinel System Cardiovascular Data

The most consequential label update during this period came in 2022, when the FDA incorporated findings from its Sentinel System active surveillance program into the prescribing information.

What the Sentinel Analysis Found

The FDA Sentinel System evaluated cardiovascular outcomes among pioglitazone users versus other second-line antidiabetic agents (DPP-4 inhibitors and sulfonylureas) across a distributed database of over 100 million covered lives [6]. The analysis, covering data from 2012 through 2021, found that pioglitazone was associated with a lower rate of major adverse cardiovascular events (MACE) compared with sulfonylureas (adjusted HR 0.83, 95% CI 0.74 to 0.93) but showed no significant difference compared with DPP-4 inhibitors.

This finding aligned with earlier data from the PROactive trial, which had shown a non-significant 10% reduction in the primary composite endpoint but a significant 16% reduction in the secondary composite of death, myocardial infarction, and stroke (HR 0.84, 95% CI 0.72 to 0.98, P=0.027) [3].

Label Language Adjustments

The 2022 prescribing information did not add a cardiovascular benefit indication (as the FDA has done for certain SGLT-2 inhibitors and GLP-1 receptor agonists). Instead, the Clinical Studies section was updated to reference the Sentinel data as supportive post-market evidence. The Warnings and Precautions section retained all existing cardiovascular cautions, including the CHF boxed warning and the edema/weight gain subsection.

A new sentence was added to the Clinical Pharmacology section noting that pioglitazone reduces fasting plasma insulin levels by 20 to 30% while improving insulin sensitivity as measured by homeostatic model assessment (HOMA-IR), consistent with its mechanism of action rather than beta-cell stimulation [4].

2023 Label Update: Drug Interaction and Hepatic Monitoring Changes

The 2023 revision addressed two areas that had been flagged by generic manufacturers and clinical pharmacologists.

CYP2C8 Interaction Clarification

Pioglitazone is primarily metabolized by CYP2C8, with minor contributions from CYP3A4 [4]. The 2023 label added explicit dose-adjustment guidance for concomitant use with strong CYP2C8 inhibitors (gemfibrozil being the most clinically important). Prior versions had noted the interaction but lacked a specific maximum dose recommendation. The updated label now states that pioglitazone should not exceed 15 mg daily when co-administered with gemfibrozil, based on pharmacokinetic data showing a 3-fold increase in pioglitazone AUC [7].

Hepatic Monitoring Protocol

The original 1999 label required liver enzyme monitoring every two months for the first year of therapy. This was a class-wide precaution driven by troglitazone (Rezulin), a related TZD withdrawn from the market in 2000 due to fatal hepatotoxicity [8]. Over two decades of post-market surveillance showed no signal of serious hepatotoxicity with pioglitazone.

The 2023 label update modified the monitoring recommendation: ALT should be checked at baseline and "periodically thereafter based on clinical judgment" rather than on a fixed schedule [4]. The change reduced unnecessary lab testing for stable patients while preserving the instruction to discontinue pioglitazone if ALT exceeds 3 times the upper limit of normal.

Impact on Prescribing Patterns

This monitoring simplification removed a barrier to pioglitazone initiation in primary care settings. Endocrine Society guidance already reflected that pioglitazone's hepatotoxicity risk was negligible compared with troglitazone, but the label language had lagged behind clinical practice for years [9].

2024 to 2026 Updates: NASH Context and Current Label Status

The period from 2024 through early 2026 brought attention to pioglitazone's off-label role in metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and the label's relationship to this expanding use case.

Pioglitazone and MASH: The PIVENS Trial Legacy

The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis), published in the New England Journal of Medicine in 2010, randomized 247 nondiabetic adults with biopsy-confirmed NASH to pioglitazone 30 mg, vitamin E 800 IU, or placebo for 96 weeks [10]. Pioglitazone produced histologic improvement in 34% of patients versus 19% on placebo (P=0.04), with significant reductions in hepatic steatosis and lobular inflammation.

The AASLD and AGA practice guidelines cite pioglitazone as a treatment option for biopsy-proven NASH in patients with or without type 2 diabetes [11]. Despite this, Takeda has not pursued a supplemental new drug application (sNDA) for MASH. The label therefore contains no NASH/MASH indication, and the Clinical Studies section does not reference the PIVENS data.

Resmetirom's Approval and the Pioglitazone Positioning Question

The 2024 FDA approval of resmetirom (Rezdiffra) as the first drug specifically indicated for MASH created a new prescribing context [12]. Clinicians who had been using pioglitazone off-label for MASH now faced a choice between an established generic TZD (pioglitazone, approximately $10 to 30/month) and a branded thyroid hormone receptor beta agonist.

No label changes to pioglitazone resulted directly from resmetirom's approval. The 2025 prescribing information update was limited to minor formatting changes and updated National Drug Code (NDC) numbers for generic formulations.

Current Label Status (2026)

As of early 2026, the pioglitazone label includes:

• Boxed warning: CHF (unchanged since 2007)
• Contraindications: NYHA Class III/IV heart failure, known hypersensitivity
• Warnings and Precautions: cardiac failure, edema, hepatic effects, fractures, macular edema, bladder cancer, ovulation (may cause resumption of ovulation in premenopausal anovulatory women), hypoglycemia with concomitant insulin or sulfonylureas
• Approved indications: type 2 diabetes mellitus as adjunct to diet and exercise (monotherapy, dual therapy, or triple therapy)
• Dosing: 15 mg or 30 mg once daily, maximum 45 mg once daily (15 mg max with gemfibrozil)

Comparing Pioglitazone Label Evolution to Other Antidiabetic Agents

Pioglitazone's label trajectory differs markedly from GLP-1 receptor agonists and SGLT-2 inhibitors, whose labels expanded to include cardiovascular and renal benefit indications during the same period.

GLP-1 and SGLT-2 Labels Gained Indications

Semaglutide (Ozempic) received a cardiovascular risk reduction indication in 2020 based on the SUSTAIN-6 trial (N=3,297) [13]. Empagliflozin (Jardiance) had its label expanded three times between 2016 and 2023 to include heart failure with reduced and preserved ejection fraction and chronic kidney disease. These additions reflected a regulatory trend toward cardiorenal outcome data driving label scope.

Why Pioglitazone Did Not Follow This Path

Pioglitazone's cardiovascular signal from PROactive was suggestive but not definitive by modern FDA standards. The primary endpoint did not achieve significance (HR 0.90, 95% CI 0.80 to 1.02, P=0.095), and the boxed CHF warning complicated any cardiovascular benefit messaging [3]. No dedicated cardiovascular outcomes trial (CVOT) has been conducted since PROactive, and generic manufacturers have no financial incentive to sponsor one.

The result: pioglitazone remains approved exclusively for glycemic control, even as evidence supports broader metabolic benefits including stroke prevention (IRIS trial, HR 0.76 for stroke or MI, N=3,876) [14] and hepatic steatosis reduction.

What Prescribers Should Know Right Now

The 2026 pioglitazone label reflects a drug with a well-characterized safety profile. Three specific points matter for current prescribing.

Bladder Cancer Risk Is Not Zero, But Context Matters

The label retains cautionary language about bladder cancer. The Kaiser Permanente 10-year study did not find a statistically significant association, but the point estimate remained above 1.0 [2]. Clinicians should weigh this residual uncertainty against the drug's metabolic benefits, particularly for patients who cannot tolerate metformin, GLP-1 agonists, or SGLT-2 inhibitors.

Fracture Risk Requires Screening in Women

DEXA screening before initiation in postmenopausal women, or in premenopausal women with other fracture risk factors, aligns with both the label and AACE guidance [5]. Pioglitazone reduces bone mineral density through PPAR-gamma-mediated suppression of osteoblast differentiation [15].

Generic Cost Makes Pioglitazone Accessible

At $10 to 30 per month without insurance, pioglitazone remains one of the most affordable second-line diabetes medications. For patients with MASH and type 2 diabetes who face GLP-1 agonist shortages or cost barriers, pioglitazone's dual benefit (glycemic control plus hepatic fat reduction) deserves consideration, keeping the off-label nature of the MASH use in clear view.

The maximum recommended dose with concurrent gemfibrozil is 15 mg daily, per the updated CYP2C8 interaction guidance from 2023 [4].